Barrons
16 Jul 2026, 09:36 UTC · 1h ago
This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Barrons
16 Jul 2026, 09:36 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Eli Lilly is in talks to acquire a psychedelic drugmaker at a premium. — A premium acquisition by a major pharma player validates the psychedelic sector and likely triggers a rally in related small-cap biotech stocks.
+0.60Which stocks this story touches
The company is expanding its pipeline through the potential acquisition of a psychedelic drugmaker.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Continue reading
6 related stories
Top 2 movers · tap to explore
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
15h ago
